Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus
暂无分享,去创建一个
C. Sotozono | B. Kaffenberger | S. Rauz | C. Sălăvăstru | E. Phillips | M. Noe | A. Mostaghimi | G. Tiplica | K. Brockow | J. Dart | M. Brüggen | B. Milpied | B. Didona | M. P. Watson | E. Gabison | B. Thong | R. Sheridan | D. Tartar | P. Romanelli | B. Ramsay | A. Brassard | C. Mortz | A. Delcampe | J. Gueudry | L. Seminario-Vidal | S. Le | J. Setterfield | E. Maverakis | A. Romano | N. Shear | J. Schulz | R. Dodiuk-Gad | P. Wolkenstein | G. Do-Pham | B. Horváth | J. Newman | S. Ingen-Housz-Oro | S. Chua | C. Chu | E. Brezinová | N. Hama | A. Paller | M. Lucas | T. H. Flynn | B. Ben Said | M. Gonçalo | D. Fortune | F. Lewis | M. Ameri | M. Torres | P. O'Reilly | S. Dridi | W. Pichler | R. Abe | V. Schmidt | L. Jörg | R. Micheletti | S. Ahmad | S. Walsh | L. French
[1] A. Barbaud,et al. Skin tests in the work‐up of cutaneous adverse drug reactions: A review and update , 2022, Contact dermatitis.
[2] T. Dowlut-McElroy,et al. Vulvovaginal involvement in pediatric Stevens-Johnson syndrome: A case series. , 2021, Journal of pediatric and adolescent gynecology.
[3] O. Dereure,et al. Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] R. Stern,et al. Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus , 2021, The British journal of dermatology.
[5] H. Lee,et al. Spectrum of Nail Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2020, JAMA dermatology.
[6] J. Lefaucheur,et al. Chronic pain: a long‐term sequela of epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) – prevalence, clinical characteristics and risk factors , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] P. Wolkenstein,et al. [Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)]. , 2020, Annales de dermatologie et de venereologie.
[8] L. French,et al. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] James X. Sun,et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. , 2020, Journal of the American Academy of Dermatology.
[10] P. Wolkenstein,et al. Health‐related quality of life and long‐term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients , 2020, The British journal of dermatology.
[11] P. Wolkenstein,et al. Individual‐ and hospital‐level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012–2016 , 2020, The British journal of dermatology.
[12] P. Wolkenstein,et al. Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate , 2020, The British journal of dermatology.
[13] Behnam Masmouei,et al. The effect of progressive muscle relaxation on anxiety and sleep quality in burn patients: A randomized clinical trial. , 2019, Burns : journal of the International Society for Burn Injuries.
[14] S. Austin,et al. Bronchiolitis obliterans as a long‐term sequela of Stevens–Johnson syndrome and toxic epidermal necrolysis in children , 2019, Clinical and experimental dermatology.
[15] M. Sengoelge,et al. Psychosocial Interventions Targeting Recovery in Child and Adolescent Burns: A Systematic Review. , 2019, Journal of pediatric psychology.
[16] J. Caubet,et al. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. , 2019, Current pharmaceutical design.
[17] P. Wolkenstein,et al. Trends in mortality rates for Stevens–Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017 , 2019, The British journal of dermatology.
[18] P. Wolkenstein,et al. Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae , 2019, The British journal of dermatology.
[19] M. Pirmohamed,et al. Controversies in drug allergy: Testing for delayed reactions. , 2019, The Journal of allergy and clinical immunology.
[20] P. Wolkenstein,et al. Post‐traumatic stress disorder in Stevens–Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients , 2018, The British journal of dermatology.
[21] E. Ramírez,et al. Assessment of drug causality in SJS/TEN: concordance between lymphocyte transformation test and ALDEN. , 2019, Allergy.
[22] C. Sotozono,et al. Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. , 2018, Investigative ophthalmology & visual science.
[23] P. Tuchinda,et al. Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS/TEN in epilepsy patients , 2018, International immunopharmacology.
[24] C. Bodemer,et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins) , 2018, Orphanet Journal of Rare Diseases.
[25] E. Phillips,et al. The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. , 2017, The journal of allergy and clinical immunology. In practice.
[26] D. Canning,et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2017, Journal of pediatric urology.
[27] D. Creamer,et al. Long‐term complications of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow‐up , 2017, The British journal of dermatology.
[28] M. Salman,et al. Vaginal Reconstruction for Vaginal Obliteration Secondary to Stevens Johnson Syndrome: A Case Report and Review of Literature. , 2017, Oman medical journal.
[29] A. Feinstein,et al. Major psychological complications and decreased health‐related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2016, The British journal of dermatology.
[30] P. Dziewulski,et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[31] P. Dziewulski,et al. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.
[32] C. Chu,et al. Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2016, Acta dermato-venereologica.
[33] P. Wolkenstein,et al. Facial Scars following Toxic Epidermal Necrolysis: Role of Adnexal Involvement? , 2016, Dermatology.
[34] L. J. Chen,et al. Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis. , 2015, The ocular surface.
[35] J. Roujeau,et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: follow‐up of pulmonary function after remission , 2015, The British journal of dermatology.
[36] A. Villa,et al. Diagnosis and management of xerostomia and hyposalivation , 2014, Therapeutics and clinical risk management.
[37] C. Sotozono,et al. Tear exchangeable limbal rigid contact lens for ocular sequelae resulting from Stevens-Johnson syndrome or toxic epidermal necrolysis. , 2014, American journal of ophthalmology.
[38] P. Wolkenstein,et al. Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents , 2014, Dermatology.
[39] S. W. Kim,et al. Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. , 2013, American journal of ophthalmology.
[40] L. Naldi,et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.
[41] P. Prabhasawat,et al. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[42] B. Milpied,et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions , 2013, The British journal of dermatology.
[43] R. Hui,et al. A patch testing and cross‐sensitivity study of carbamazepine‐induced severe cutaneous adverse drug reactions , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[44] M. Laufer,et al. Prevention of vulvovaginal sequelae in stevens-johnson syndrome and toxic epidermal necrolysis. , 2011, Reviews in obstetrics & gynecology.
[45] S. Doan,et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2009, American journal of ophthalmology.
[46] J. Roujeau,et al. Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. , 2009, Archives of dermatology.
[47] G. Soubrane,et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2009, Archives of dermatology.
[48] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[49] T. Shiohara,et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption , 2007, Allergy.
[50] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[51] J. Roujeau,et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.
[52] J. Roujeau,et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.
[53] J. Roujeau,et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens‐Johnson syndrome and toxic epidermal necrolysis , 1996, Contact dermatitis.
[54] C. Foster,et al. Penetrating keratoplasty in cicatrizing conjunctival diseases. , 1995, Ophthalmology.
[55] R. Snaith,et al. The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.